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the major capsid protein and self-assembles into viruslike
particles (VLPs). Species-specific VLP vaccines provide
protection against infection and disease. Protection was
associated with the development of neutralizing antibod-
ies. Serum from vaccinated animals conferred protection
to unvaccinated animals. 
The HPV-6, HPV-11, HPV-16, and HPV-18 L1 VLP
vaccine is manufactured in Saccharomyces cerevisiae
(yeast), and yeast-derived vaccines have been given to mil-
lions of children and adults. The vaccine includes amor-
phous aluminum hydroxyphosphate sulfate adjuvant and is
given in a 0-, 2-, 6-month dosing scheme. Phase I trials
(300 participants) were performed to establish immuno-
genicity and tolerability of a range of doses of monovalent
HPV L1 vaccines. Phase II trials (3,500 participants) were
performed to establish the immunogenicity and tolerabili-
ty of a range of HPV L1 VLP vaccine dose formulations
and provide preliminary proof of concept. Phase III trials
(20,000 participants) will determine the efficacy of the
HPV L1 VLP vaccine by using prevention of type-related
CIN I, genital warts, and CIN II/III as the endpoints.
The results of the phase II trial of the HPV-16 VLPvac-
cine have been recently published (1). The primary end-
point of this trial in 2,392 young women was persistent
HPV-16 infection (detection in consecutive visits) and
HPV-16-related CIN. In 16- to 23-year-old women who
were HPV-16-naïve at baseline, the vaccine was 100%
effective; HPV-16 and CIN were detected in 41 unvacci-
nated (placebo) women and in no vaccinated women. The
vaccine was generally well tolerated, and no serious vac-
cine-related adverse events were seen. 
The phase III efficacy trial addressing women 16–-23
years is underway. Approximately 25,000 women in 33
countries and 100 sites have been enrolled. The evaluation
includes Pap testing and HPV polymerase chain reaction at
defined intervals. An adolescent program (for girls 9-15
years of age) is ongoing to demonstrate vaccine immuno-
genicity and tolerability in boys and girls. In addition, a
study with Nordic Cancer Registries is planned for long-
term (>10 years) follow-up postlicensure to determine
duration of efficacy, long-term safety, and replacement of
vaccine types with other HPVs. Phase III programs will
definitively evaluate clinical and public health impact of
the HPV vaccine in adolescents and adult women.
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Impact of HIV on Women
Internationally
Women bear about half of the HIV infections world-
wide. In sub-Saharan Africa, 58% of those infected are
women; in Asia this figure is 30%. While the epidemic
occurs in varied geographic regions, all women are biolog-
ically and socioculturally vulnerable. 
Our common prevention options fail to take into
account women’s realities: being in, or wanting to be in, a
union; wanting to have children; the imbalance of power in
male/female relationships; inaccessibility of education; the
threat of sexual violence; and the economic vulnerability
that leads to engaging in sexual activity for survival.
Female-controlled methods, including female condoms
and microbicides, are essential and must take into account
these realities. The prevention needs of women already
infected with HIV must be addressed by supporting disclo-
sure, fighting stigma, and being sensitive to the threat of
violence and disinheritance. 
The burden of care for those living with HIV/AIDS
most often falls to women and girls. Recognition of the
value of this work is vital, as is addressing practical issues
that can help alleviate this burden of care.
HIV-Positive Women's Perspective, 
Advocacy, Sexual and Reproductive Rights
Biomedical, social, and human rights factors are com-
pelling reasons for giving particular attention to women
and HIV. However, research on women and HIV/AIDS in
terms of treatment, adherence, and opportunistic infections
is deficient. Women lack access to treatment, and women's
representation in treatment advocacy initiatives remains
wanting. 
In terms of sexual and reproductive health, women face
barriers in accessing treatment for sexually transmitted
infections and have inadequate access to prophylactic
treatments such as Pap smears and sexual health screen-
ings. Female condoms are often unobtainable, and acceler-
ated research on woman-controlled barriers is needed.
Many programs for HIV-positive women lack services to
support safe conception, frequently consider women only
or primarily in terms of reproduction, and can unethically
deny HIV-positive women reproductive health services. 
Scientific research, programs, and initiatives should
focus on HIV-positive women and their interrelation with
treatment, adherence, opportunistic infections, female-
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These findings must then be translated into ethical policy
and practice. 
HIV among Young Women in 
Developing Countries
Youths (persons 15–24 years of age) are a major part of
the HIV epidemic around the world, making up an estimat-
ed half of new HIV infections, and young women are typ-
ically infected earlier than are men. Young women have
both biological and social vulnerabilities. They can be sus-
ceptible to “sugar daddy” relationships, they are vulnera-
ble to sex trafficking or coercion, and they have less
education, including HIV prevention education, than their
male counterparts. Some countries have had success in
reducing HIV among young women; however, many pro-
gram challenges remain: lack of evaluation, limited
resources, the unique vulnerabilities of youth ignored, and
the lack of influence by young persons. 
Fifteen million children 15 years of age and younger
have lost one or both parents to AIDS, and this situation
also presents challenges, including increased risk of sexu-
al exploitation, the loss of educational opportunities as
young people are forced to leave school because they lack
school funds or must work to support remaining family
members, and the need for HIV prevention education that
addresses orphans' special needs.
Some promising youth programs have been initiated,
among them curriculum-based programs, peer education,
and voluntary counseling and testing; however, more
resources and evaluation must be devoted to youth pro-
grams, and these programs should view youth as assets,
not as problems. 
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Hepatitis B in Women:
Domestically and
Internationally
Globally, hepatitis B virus (HBV) infection is a major
cause of infectious disease-related death, causing approxi-
mately 620,000 deaths annually. Without hepatitis B vac-
cination, an estimated 1.4 million HBV-related deaths
would occur in the 2000 birth cohort over the lifetime of
the cohort. HBV infections acquired in the perinatal and
early childhood periods account for 21% and 48%, respec-
tively, of HBV-related deaths worldwide. Thus, routine
vaccination of infants and children serves as the basis for a
global hepatitis B prevention program. 
In 1992, the World Health Organization recommended
that hepatitis B vaccine be included in childhood immu-
nization programs in all countries, but because of financial
constraints, many countries were unable to initially imple-
ment this recommendation. In 1999, a global initiative
began to make hepatitis B vaccine available to children liv-
ing in 69 of the world's poorest countries, and by the end
of 2003, routine childhood hepatitis B vaccination was
included in national immunization programs in  >151
countries. However, many countries, mainly in sub-
Saharan Africa, have not yet introduced the vaccine, and
coverage with the three-dose vaccination series remains
low in many countries that have introduced the vaccine.
When all countries have introduced the vaccine and cover-
age with the three-dose vaccination series reaches 90%, up
to 84% of global HBV-related deaths will be prevented.
Hepatitis B in the United States
In the United States, an estimated 5% of the civilian,
noninstitutionalized population has serologic evidence of
past or present HBV infection, and 0.4%-0.5% have chron-
ic infection and are the primary source of infection for oth-
ers. From 1990 through 2002, the incidence of reported
acute hepatitis B declined 67%. The incidence of acute
hepatitis B among men has been consistently higher than
among women. In 1990, the incidence among men and
women was 9.8 and 6.3 per 100,000, respectively; in 2002,
the incidence was 3.7 and 2.2 per 100,000, respectively.
Overall, incidence among women has declined more than
among men. Trends in acute hepatitis B reflect poor vacci-
nation coverage among persons who engage in high-risk
behavior.
Persons at high risk for HBVinfection often seek health
care in settings in which vaccination services could be pro-
vided. During 1996–1998, approximately half of persons
with reported acute hepatitis B previously had been treat-
ed for a sexually transmitted disease (STD) or incarcerat-
ed: 89% of injection drug users, 35% of men who have sex
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Audio tapes of all sessions are available for purchase from
Conference Archives, 239 Main Street, Suite 300,
Johnstown, Pennsylvania 15901; telephone: 866-316-3289
or at http://www.conferencearchives.com/cgi-bin/caistore/
CDR040207.html